Do New Drugs Prolong Lives?
Billy Tauzin, president and CEO of PhRMA, the drug industry's US trade association, is a cancer survivor and gives credit to new expensive drugs...
What a Difference a Day Makes!
In just one day the world changed! And it changed for the better. Was it good for you too?Of course, I'm talking about Sepracor,...
CommonHealth’s Selective Release of DTC Study Data
CommonHealth's MBS/Vox division conducted a study of 440 physician-patient conversations, which according to industry reports -- and I'm quoting a story in the October...
Clear Words, Obscure Benefits
Next Tuesday at 3:05 PM, I am scheduled to give a presentation entitled "Obscure words, clear benefits" at the eyeforpharma "e-Communication and Online Marketing"...
Lunesta, Google, and “bAdWords”
Last week I wrote about the online Sleep drug ad wars (see "AmbienCR and Lunesta Duke It Out on Web").Today I focus on the...
Marketer vs. Marketeer: Synonymous?
I've attended many pharmaceutical marketing conferences and heard some speakers refer to themselves are 'marketers' and some as 'marketeers.'I prefer "marketer." For one thing,...
Rozerem Sleeper Cell at Pri-Med Conference
At the DTC in the New Era conference last week, I heard an interesting statement from Dale Taylor, President & CEO of AbelsonTaylor, Inc.,...
Teaching New Dogs Old Tricks
Professor Jim Avery at University of Oklahoma's Gaylord College of Mass Communication discusses preparing graduate students for a career in health advertising.
AmbienCR and Lunesta Duke It Out on Web
AmbienCR and Lunesta are battling for the leader position in the sleep aid market and are currently "duking it out" on the Internet via...
Awards: The Good, The Bad, The Ugly
Everybody likes to win awards and there are many awards for advertising and for pharmaceutical industry advertising in particular.DTC Perspectives, a fine trade publication...
